Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Hematology
How would you treat T-cell/Histiocyte-rich Large B cell Lymphoma transformed from Nodular Lymphocyte-Predominant Hodgkin Lymphoma?
Would you choose more intensive frontline therapy than R-CHOP?
Related Questions
What factors do you consider when sequencing bispecific T-cell engaging antibodies and CAR T-cell therapies for the treatment of follicular lymphoma?
What subsequent therapies did patients receive after progressing on pirtobrutinib in the mantle cell BRUIN trial population?
Would you offer XRT as bridging for all patients with limited pre CAR-T disease or as consolidation for only those with residual PET-avidity on day+30 post CAR-T?
What is your standard approach to treatment of plasmablastic lymphoma in HIV negative patients?
How do you choose between axicabtagene ciloleucel and tisagenlecleucel in patients with follicular lymphoma for whom you are recommending CAR T-cell therapy?
How would you treat an otherwise healthy patient with newly diagnosed Stage IIA unfavorable classical Hodgkin lymphoma who has exceeded lifetime anthracycline dose (for other indications, not treated previously for Hodgkins)?
Is your standard of care for newly diagnosed advanced classical Hodgkin now nivolumab-AVD based on SWOG 1826?
How are you deciding between available third line therapies for post-transplant relapsed DLBCL?
How would you treat a patient with Hodgkin lymphoma who has an isolated relapse within the CNS?
What is your preferred second line regimen for follicular lymphoma that has relapsed four years out since receiving BR?